Monoclonal antibodies, such as cetuximab and panitumumab, target the extracellular domain of EGFR to block ligand binding and intracellular signaling, thus inhibiting tumor cell proliferation, angiogenesis, and metastasis [89]. Here, EGFR is linked to neoplasm.